0.4655
price up icon6.04%   0.0265
after-market After Hours: .45 -0.0155 -3.33%
loading
Aditxt Inc stock is traded at $0.4655, with a volume of 222.52K. It is up +6.04% in the last 24 hours and down -53.31% over the past month. Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
See More
Previous Close:
$0.439
Open:
$0.44
24h Volume:
222.52K
Relative Volume:
0.09
Market Cap:
$1.68M
Revenue:
$749.50K
Net Income/Loss:
$-29.60M
P/E Ratio:
-0.00124
EPS:
-376.0263
Net Cash Flow:
$-22.09M
1W Performance:
-27.50%
1M Performance:
-53.31%
6M Performance:
-86.62%
1Y Performance:
-98.59%
1-Day Range:
Value
$0.4164
$0.4757
1-Week Range:
Value
$0.4164
$0.65
52-Week Range:
Value
$0.4164
$35.90

Aditxt Inc Stock (ADTX) Company Profile

Name
Name
Aditxt Inc
Name
Phone
909-488-0844
Name
Address
737 N. FIFTH STREET, SUITE 200, RICHMOND
Name
Employee
47
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ADTX's Discussions on Twitter

Aditxt Inc Stock (ADTX) Latest News

pulisher
Sep 05, 2024

Aditxt Inc: Rising -98.90% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle

Sep 05, 2024
pulisher
Sep 04, 2024

ADTX stock touches 52-week low at $0.54 amid market challenges - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Aditxt subsidiary seeks $2M for prostate cancer test - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients - StockTitan

Sep 04, 2024
pulisher
Sep 02, 2024

Is Aditxt Inc (ADTX) worth investing in despite its overvalued state? - US Post News

Sep 02, 2024
pulisher
Sep 02, 2024

Prepare Yourself for Liftoff: Aditxt Inc (ADTX) - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Ratio Examination: Aditxt Inc (ADTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 02, 2024
pulisher
Aug 29, 2024

Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024 - Quantisnow

Aug 29, 2024
pulisher
Aug 28, 2024

Aditxt extends senior note maturity to September 30 By Investing.com - Investing.com Australia

Aug 28, 2024
pulisher
Aug 28, 2024

Aditxt extends senior note maturity to September 30 By Investing.com - Investing.com Canada

Aug 28, 2024
pulisher
Aug 28, 2024

Aditxt extends senior note maturity to September 30 - Investing.com

Aug 28, 2024
pulisher
Aug 28, 2024

Aditxt extends senior note maturity to September 30 By Investing.com - Investing.com UK

Aug 28, 2024
pulisher
Aug 27, 2024

Aditxt Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - The InvestChronicle

Aug 27, 2024
pulisher
Aug 27, 2024

Stock Market Recap: Aditxt Inc (ADTX) Concludes at 0.79, a -11.70 Surge/Decline - The Dwinnex

Aug 27, 2024
pulisher
Aug 27, 2024

Pearsanta appoints Christopher Mitton as President By Investing.com - Investing.com Australia

Aug 27, 2024
pulisher
Aug 26, 2024

Pearsanta appoints Christopher Mitton as President - Investing.com

Aug 26, 2024
pulisher
Aug 26, 2024

Pearsanta appoints Christopher Mitton as President By Investing.com - Investing.com Canada

Aug 26, 2024
pulisher
Aug 26, 2024

Pearsanta appoints Christopher Mitton as President - Investing.com India

Aug 26, 2024
pulisher
Aug 26, 2024

ADTXAditxt, Inc. Latest Stock News & Market Updates - StockTitan

Aug 26, 2024
pulisher
Aug 26, 2024

Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™) - Quantisnow

Aug 26, 2024
pulisher
Aug 26, 2024

Pearsanta appoints Christopher Mitton as President By Investing.com - Investing.com UK

Aug 26, 2024
pulisher
Aug 26, 2024

Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™) - Elk Valley Times

Aug 26, 2024
pulisher
Aug 26, 2024

Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™) - StockTitan

Aug 26, 2024
pulisher
Aug 24, 2024

ADTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Australia

Aug 24, 2024
pulisher
Aug 24, 2024

500: Something went wrong - Investing.com India

Aug 24, 2024
pulisher
Aug 23, 2024

ADTX stock touches 52-week low at $0.88 amid market challenges - Investing.com

Aug 23, 2024
pulisher
Aug 23, 2024

ADTX stock touches 52-week low at $0.88 amid market challenges - Investing.com UK

Aug 23, 2024
pulisher
Aug 21, 2024

Aditxt extends Appili acquisition deadline to November 19 - Investing.com

Aug 21, 2024
pulisher
Aug 21, 2024

Evofem Biosciences amends merger agreement with Aditxt By Investing.com - Investing.com Australia

Aug 21, 2024
pulisher
Aug 21, 2024

Aditxt extends Appili acquisition deadline to November 19 By Investing.com - Investing.com Australia

Aug 21, 2024
pulisher
Aug 21, 2024

Aditxt extends Appili acquisition deadline to November 19 By Investing.com - Investing.com UK

Aug 21, 2024
pulisher
Aug 21, 2024

ADTX’s Stock Dilemma: Aditxt Inc’s Market Performance and Outlook - The InvestChronicle

Aug 21, 2024
pulisher
Aug 21, 2024

Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics - Elk Valley Times

Aug 21, 2024
pulisher
Aug 21, 2024

Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics - Quantisnow

Aug 21, 2024
pulisher
Aug 21, 2024

Appili Therapeutics Modifies Acquisition Deal with Aditxt - TipRanks

Aug 21, 2024
pulisher
Aug 21, 2024

Market Update: Aditxt Inc (ADTX) Sees Negative Movement, Closing at 0.95 - The Dwinnex

Aug 21, 2024
pulisher
Aug 21, 2024

Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt - Yahoo Finance

Aug 21, 2024
pulisher
Aug 21, 2024

Evofem Biosciences amends merger agreement with Aditxt - Investing.com

Aug 21, 2024
pulisher
Aug 20, 2024

Evofem Biosciences amends merger agreement with Aditxt By Investing.com - Investing.com UK

Aug 20, 2024
pulisher
Aug 20, 2024

ADTX Stock Earnings: Aditxt Reported Results for Q2 2024 - MSN

Aug 20, 2024
pulisher
Aug 19, 2024

ADTX Stock Earnings: Aditxt Reported Results for Q2 2024 - InvestorPlace

Aug 19, 2024
pulisher
Aug 16, 2024

Aditxt (NASDAQ:ADTX) Stock Quotes, Forecast and News Summary - Benzinga

Aug 16, 2024
pulisher
Aug 14, 2024

Short Interest in Aditxt, Inc. (NASDAQ:ADTX) Increases By 81.5% - Defense World

Aug 14, 2024
pulisher
Aug 14, 2024

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 - StreetInsider.com

Aug 14, 2024
pulisher
Aug 14, 2024

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 - StockTitan

Aug 14, 2024
pulisher
Aug 13, 2024

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025 - BioSpace

Aug 13, 2024
pulisher
Aug 13, 2024

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025 - StockTitan

Aug 13, 2024
pulisher
Aug 13, 2024

Aditxt shareholders approve strategic proposals - Investing.com

Aug 13, 2024
pulisher
Aug 13, 2024

Aditxt shareholders approve strategic proposals - Investing.com India

Aug 13, 2024
pulisher
Aug 13, 2024

Aditxt shareholders approve strategic proposals By Investing.com - Investing.com Australia

Aug 13, 2024
pulisher
Aug 13, 2024

Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders' Meeting, Setting the Stage for 2024 and 2025 Strategic Plans - Quantisnow

Aug 13, 2024

Aditxt Inc Stock (ADTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$84.08
price down icon 1.22%
$27.52
price down icon 0.61%
$191.32
price down icon 0.14%
$89.94
price down icon 0.23%
$72.89
price down icon 0.75%
$246.78
price down icon 1.87%
Cap:     |  Volume (24h):